BioSpace News Archive

Altamira Therapeutics Ltd. announced positive top-line data from its exploratory Phase 2 TRAVERS trial with AM-125 in acute vertigo and provided an update on its development plans.

Royal Philips announced the latest results from the Tack Optimized Balloon Angioplasty II below-the-knee clinical trial, demonstrating that the Philips endovascular system – Tack – the first and only device of its kind approved by the U.S. Food and Drug Administration, provides a sustained treatment effect and positive impact on quality of life for patients with critical limb ischemia, a severe stage of peripheral arterial disease, out to three years of clinical follow-up.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), today announced that it has completed enrollment and dosing of its Phase 1b CLEAR clinical study to evaluate safety and efficacy of intranasal REVTx-99b for the treatment of allergic rhinitis.

Hollister Incorporated, a global medical device company, has been awarded a three-year group purchasing agreement for Urological products with vizient, Inc., the nation’s largest member-driven health care performance improvement company.

Airway Management, Dallas-based manufacturer of the most independently studied custom oral appliance in the world, announces their non-custom myTAP™ is now proven equally effective to their custom TAP™.

Amsterdam, the Netherlands – Royal Philips announced that it will repurchase up to 3.2 million shares to cover certain of its obligations arising from its long-term incentive and employee stock purchase plans.

Asep Medical Holdings Inc. (“Asep Inc.” or the “Company”) (CSE: ASEP) (OTCQB: SEPSF) is pleased to announce that the Company has received an official allowance of its patent claims that serve as the foundation underlying their first-generation sepsis diagnostic technology, SepsetER.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) presented data at The Endocrine Society Annual Meeting, ENDO 2022, demonstrating the Company’s ongoing commitment to understanding the lifetime impact of achondroplasia, the most common form of disproportionate short stature.

Oxurion NV(Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that two presentations were delivered at The Macula Society 45th Annual Meeting, June 8 -11, 2022 in Berlin, Germany.

The U.S. Food and Drug Administration approved Olumiant oral tablets to treat adult patients with severe alopecia areata, a disorder that often appears as patchy baldness and affects more than 300,000 people in the U.S. each year.